Icon

APRETUDE (nda215499)- (600MG/3ML (200MG/ML))

CABOTEGRAVIR VIIV HLTHCARE
600MG/3ML (200MG/ML)
No No
2031-Sep-15 2026-Jan-21
None None
None No
APRETUDE is an HIV-1 integrase strand transfer inhibitor (INSTI) indicated in at-risk adults and adolescents weighing at least 35 kg for PrEP to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP.
0 0 0
Total Other Developers 2
Drugs with Suitability No
600MG/3ML (200MG/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.